Norelgestromin

For the prevention of pregnancy, the standard dosage for the norelgestromin/ethinyl estradiol transdermal system is as follows:

• Standard Regimen: One patch is applied and worn for a full seven days (one week). This process is repeated for three consecutive weeks (Total of 21 days). This is followed by a "patch-free" week (7 days) during which withdrawal bleeding (similar to a period) usually occurs.
• Dose Strength: The patch delivers 150 mcg of norelgestromin and 35 mcg of ethinyl estradiol per 24 hours.
• Cycle Start: The first patch is typically applied on either the first day of the menstrual period (Day 1 Start) or the first Sunday following the start of the period (Sunday Start). If using the Sunday Start, a non-hormonal backup method (like condoms) must be used for the first 7 days of the first cycle.

Norelgestromin is not indicated for use in pediatric patients before the onset of menarche (the first menstrual period). For adolescent females who have reached menarche, the dosage is the same as the adult dosage. Safety and efficacy have been established in females of reproductive age, but it is not intended for use in children who have not yet begun menstruating.

Renal Impairment

There are no specific dosage adjustments provided in the manufacturer's labeling for patients with renal impairment. However, since hormones are metabolized and excreted, patients with severe renal disease should be monitored closely by their healthcare provider.

Hepatic Impairment

Norelgestromin is contraindicated in patients with acute or chronic hepatocellular disease (liver disease) or liver tumors (benign or malignant). The liver is the primary site for the metabolism of these hormones; impaired liver function can lead to toxic accumulation.

Elderly Patients

Norelgestromin is not indicated for use in postmenopausal women. It is intended for use only in females of reproductive age.

1. 1Application Site: Apply the patch to clean, dry, intact skin on the buttock, abdomen, upper outer arm, or upper torso. Do not apply the patch to the breasts or to skin that is red, irritated, or cut.
2. 2Skin Preparation: Avoid applying lotions, creams, oils, or powders to the area where the patch will be placed, as this may cause the patch to detach.
3. 3Application Technique: Press down firmly on the patch with the palm of your hand for 10 seconds, ensuring the edges are well-adhered.
4. 4Rotation: Each new patch should be applied to a different spot on the skin to avoid irritation (site rotation).
5. 5Checking the Patch: Check the patch daily to ensure it is still adhering properly.
6. 6Storage: Store patches in their original foil pouches at room temperature (20°C to 25°C or 68°F to 77°F). Do not refrigerate or freeze.

If a patch is partially or completely detached for:

• Less than 24 hours: Try to reapply it or replace it with a new patch immediately. No backup contraception is needed. Your "Patch Change Day" remains the same.
• More than 24 hours (or unknown duration): Stop the current cycle and start a new 4-week cycle immediately by applying a new patch. This is now your new "Day 1" and new "Patch Change Day." You must use a non-hormonal backup method (e.g., condoms) for the first 7 days of the new cycle.

If you forget to change your patch at the start of any patch cycle (Week 1, Day 1):

• Apply the new patch as soon as you remember. This is your new "Patch Change Day." Use backup contraception for the first 7 days.

Symptoms of an overdose of hormonal contraceptives may include nausea, vomiting, and withdrawal bleeding in females. In case of a suspected overdose (e.g., a child applying multiple patches), remove all patches immediately and contact a poison control center or seek emergency medical attention. While not life-threatening in most cases, excessive hormone exposure requires medical observation.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your schedule or skip weeks without medical guidance, as this significantly increases the risk of unintended pregnancy.

Most users of norelgestromin-based patches experience some mild side effects, particularly during the first 2-3 months of use as the body adjusts to the hormones. Common reactions include:

• Application Site Reactions: Up to 17% of users report redness, itching, or irritation where the patch was applied. This usually resolves after moving the patch to a new location.
• Breast Tenderness: Hormonal fluctuations can cause breast swelling or sensitivity (mastalgia).
• Headache: Including tension-type headaches and, in some cases, an increase in migraine frequency.
• Nausea: Often experienced during the first cycle; taking the medication via a patch rather than a pill may reduce but does not eliminate this symptom.
• Menstrual Cramps: Dysmenorrhea or changes in the intensity of period pain.

• Mood Swings: Feelings of anxiety, irritability, or depression.
• Weight Gain: Slight increases in weight due to fluid retention or changes in appetite.
• Dizziness: Occasional lightheadedness.
• Acne: While some find their acne improves, others may experience hormonal breakouts.
• Vaginal Infections: Increased susceptibility to yeast infections (candidiasis) or changes in vaginal discharge.

• Increased Blood Pressure: Hormonal contraceptives can cause a clinically significant rise in blood pressure in some women.
• Chloasma: Darkening of the skin, particularly on the face (also known as the "mask of pregnancy"). This may be permanent.
• Gallbladder Disease: Increased risk of gallstones or cholestasis.
• Glucose Intolerance: Changes in how the body processes sugar, which is particularly relevant for women with pre-diabetes.

> Warning: Stop taking Norelgestromin and call your doctor immediately or seek emergency care if you experience any of the following symptoms (often referred to by the acronym ACHES):

• A - Abdominal Pain: Severe pain in the stomach or abdomen could indicate a liver tumor or gallbladder problem.
• C - Chest Pain: Sharp pain in the chest, shortness of breath, or coughing up blood, which may indicate a pulmonary embolism (blood clot in the lung) or heart attack.
• H - Headaches: Sudden, severe headaches, especially if accompanied by vision changes, numbness, or weakness, which could signal a stroke.
• E - Eye Problems: Blurred vision, double vision, or loss of vision, which may indicate a retinal vascular thrombosis (clot in the eye).
• S - Severe Leg Pain: Swelling, redness, or warmth in the calf or thigh, which are signs of deep vein thrombosis (DVT).

• Bone Mineral Density: While not as significant as with some other contraceptives, long-term use of hormones can slightly influence bone turnover.
• Cancer Risk: There is a complex relationship between hormonal contraceptives and cancer. Use is associated with a slight increase in the risk of breast and cervical cancer diagnosis, but a significant decrease in the risk of ovarian, endometrial, and colorectal cancers.
• Liver Health: Long-term use is associated with a very rare risk of hepatic adenomas (benign liver tumors) which can rupture and cause internal bleeding.

Cigarette Smoking and Serious Cardiovascular Events

Cigarette smoking increases the risk of serious cardiovascular side effects from combined hormonal contraceptive (CHC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, CHCs, including the norelgestromin patch, are contraindicated in women who are over 35 years of age and smoke.

BMI and Thromboembolism Risk

Some labels also carry warnings regarding BMI. The norelgestromin patch is contraindicated in women with a BMI ≥ 30 kg/m² because the risk of thromboembolic events is higher in this group and the efficacy of the patch is reduced.

Report any unusual symptoms to your healthcare provider immediately. Early detection of serious side effects is critical for safety.

Norelgestromin is a potent hormone that affects multiple systems in the body. It is vital to understand that the transdermal patch delivers a continuous dose of estrogen and progestin, which may result in higher steady-state estrogen levels compared to some low-dose oral contraceptives. This can potentially correlate with a higher risk of blood clots.

Warning: Smoking and Cardiovascular Events

According to the FDA-approved labeling, women who use combined hormonal contraceptives, including norelgestromin, should be strongly advised not to smoke. Smoking significantly increases the risk of serious cardiovascular events, including myocardial infarction (heart attack) and stroke. This risk is highest in women over age 35 who smoke 15 or more cigarettes per day.

Warning: BMI Limitations

Norelgestromin/ethinyl estradiol patches are contraindicated for use in women with a BMI ≥ 30 kg/m². Clinical data indicates that these women have a higher risk of developing venous thromboembolism (VTE) compared to women with lower BMIs. Additionally, the patch may be less effective at preventing pregnancy in women weighing more than 198 lbs (90 kg).

• Thromboembolism Risk: The risk of VTE (Deep Vein Thrombosis and Pulmonary Embolism) is highest during the first year of using a hormonal contraceptive or when restarting after a break of 4 weeks or more.
• Hypertension: Norelgestromin can cause an increase in blood pressure. Women with uncontrolled hypertension should not use this medication.
• Liver Toxicity: Discontinue use if jaundice (yellowing of the skin or eyes) or acute liver disturbances occur. The drug is contraindicated in those with active hepatitis.
• Lipid Metabolism: Progestins like norelgestromin can alter lipid profiles. Women with uncontrolled dyslipidemia (high cholesterol/triglycerides) should be monitored closely.
• Fluid Retention: Because hormones cause fluid retention, conditions like epilepsy, migraine, asthma, and cardiac or renal dysfunction may be exacerbated.

Patients using norelgestromin should undergo the following regularly:

• Blood Pressure: Checked at least annually.
• Cytological Screening: Regular Pap smears and pelvic exams as recommended by the ACOG (American College of Obstetricians and Gynecologists).
• Breast Exams: Regular self-exams and clinical exams to monitor for lumps.
• Liver Function: If symptoms of hepatic impairment arise.
• Glucose Levels: For women with a history of gestational diabetes or pre-diabetes.

Norelgestromin generally does not interfere with the ability to drive or operate machinery. However, if you experience side effects like dizziness or vision changes, avoid these activities and consult your doctor.

There is no direct contraindication between alcohol consumption and norelgestromin. However, heavy alcohol use can stress the liver, which is also responsible for processing the hormones in the patch. Moderation is advised.

If you decide to stop using norelgestromin, you can do so at any time by simply removing the patch. Fertility typically returns quickly, often within the first cycle after discontinuation. If you are stopping the patch but do not wish to become pregnant, you must start an alternative contraceptive method immediately.

> Important: Discuss all your medical conditions, especially any history of blood clots, heart disease, or breast cancer, with your healthcare provider before starting Norelgestromin.

• Hepatitis C Combinations: Do not use norelgestromin with combination drug regimens containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir. This can lead to significant elevations in liver enzymes (ALT).
• Anastrozole/Exemestane: These breast cancer medications (aromatase inhibitors) can have their efficacy reduced by the hormones in the patch.

• CYP3A4 Inducers: Drugs that induce the cytochrome P450 3A4 enzyme can speed up the metabolism of norelgestromin, leading to lower blood levels and potential contraceptive failure (breakthrough pregnancy). Examples include:
• Anticonvulsants: Phenytoin, carbamazepine, oxcarbazepine, topiramate, and phenobarbital.
• Antibiotics: Rifampin and rifabutin.
• HIV Protease Inhibitors: Medications like ritonavir, nelfinavir, and nevirapine can significantly alter the levels of norelgestromin.
• Lamotrigine: Combined hormonal contraceptives have been shown to significantly decrease the plasma concentration of lamotrigine, potentially increasing the risk of seizures. Dose adjustments of lamotrigine may be necessary.

• Antibiotics: While most common antibiotics (like amoxicillin) are no longer thought to interfere with the patch, some providers still recommend backup contraception during short courses of therapy to be safe.
• Colesevelam: This cholesterol medication can bind to hormones in the gut if taken orally; while less of a concern with the patch, it is still noted in general hormonal interaction databases.
• Cyclosporine: Norelgestromin may increase the plasma concentrations of cyclosporine, increasing the risk of toxicity.

• Grapefruit Juice: Grapefruit is a known inhibitor of CYP3A4. While the patch bypasses the gut, systemic inhibition of the enzyme could theoretically increase the levels of norelgestromin in the blood, potentially increasing side effects.
• Caffeine: Hormonal contraceptives can decrease the clearance of caffeine, making you feel more "jittery" or anxious after your morning coffee.

• St. John's Wort: This herbal supplement is a potent inducer of liver enzymes. It is well-documented to cause contraceptive failure and breakthrough bleeding in women using hormonal methods. Do not use St. John's Wort while using norelgestromin.
• Vitex (Chasteberry): May interfere with the hormonal feedback loop and reduce the efficacy of the contraceptive.

Norelgestromin can affect the results of several laboratory tests, including:

• Thyroid Function: Increased thyroid-binding globulin (TBG) leading to increased total T4 levels (though free T4 remains normal).
• Coagulation Factors: Increases in prothrombin and factors VII, VIII, IX, and X.
• Glucose Tolerance: May decrease glucose tolerance in some users.

For each major interaction, the mechanism involves either the induction of enzymes (leading to reduced efficacy) or the inhibition of enzymes/displacement of protein binding (leading to increased toxicity). Always manage these by consulting your doctor and using a backup barrier method of contraception.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, as many substances can make the patch less effective.

Norelgestromin must NEVER be used in the following circumstances:

• History of Thromboembolic Disorders: Including Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or current/past history of stroke or myocardial infarction. The hormones increase the risk of fatal blood clots.
• BMI ≥ 30 kg/m²: Due to the significantly elevated risk of VTE and reduced efficacy in this population.
• Breast Cancer: Or any other estrogen- or progesterone-sensitive cancer, as hormones can stimulate tumor growth.
• Liver Disease: Acute hepatitis, severe cirrhosis, or liver tumors (adenomas or carcinomas).
• Undiagnosed Abnormal Uterine Bleeding: Bleeding must be evaluated to rule out malignancy before starting hormones.
• Pregnancy: Norelgestromin has no role in pregnancy and may cause harm to the developing fetus.
• Smoking and Age > 35: Women over 35 who smoke any amount of cigarettes should not use the patch.
• Migraine with Aura: This specific type of migraine is associated with a much higher risk of ischemic stroke when combined with hormonal contraceptives.

Conditions requiring a careful risk-benefit analysis by a physician include:

• Gallbladder Disease: History of cholestasis related to pregnancy or previous pill use.
• Controlled Hypertension: Requires frequent monitoring.
• Diabetes Mellitus: Especially with vascular involvement (e.g., neuropathy or retinopathy).
• Hypertriglyceridemia: A family history of very high triglycerides increases the risk of pancreatitis when using hormones.

Patients with a known hypersensitivity to norelgestromin, norgestimate, or any component of the transdermal system (including the adhesives) should not use the patch. If you have had an allergic reaction to other progestins, discuss this with your doctor.

> Important: Your healthcare provider will evaluate your complete medical history, including family history of heart disease and cancer, before prescribing Norelgestromin.

Norelgestromin is classified as Pregnancy Category X (under the old FDA system) and is strictly contraindicated during pregnancy. There is no reason to use hormonal contraceptives once pregnancy has occurred. While accidental exposure during early pregnancy has not been definitively linked to birth defects in large-scale studies, the drug should be discontinued immediately if pregnancy is confirmed. It is not used in fertility treatments.

Hormonal contraceptives containing estrogens and progestins can decrease the quantity and quality of breast milk. Small amounts of norelgestromin are excreted in human milk. It is generally recommended that breastfeeding mothers wait until the infant is fully weaned or use progestin-only methods (like the "mini-pill" or certain IUDs) before starting a combined patch like norelgestromin.

Safety and efficacy have been established in females of reproductive age. Use in prepubertal children is not indicated. In adolescent females, the primary concern is the potential effect on bone mineral density, though most studies suggest that the benefits of pregnancy prevention outweigh the risks once menarche has been established. Pediatric dosing is identical to adult dosing for those who have reached menarche.

Norelgestromin is not indicated for use in postmenopausal women. Clinical studies did not include women over the age of 65. In older premenopausal women (age 40-50), the risk of cardiovascular events and breast cancer should be weighed against the benefits of cycle regulation and contraception.

Specific studies in patients with renal impairment have not been conducted. However, because the hormones are metabolized by the liver and the metabolites are excreted by the kidneys, caution is advised in patients with end-stage renal disease (ESRD). Dialysis does not significantly clear these steroid hormones.

Norelgestromin is contraindicated in patients with significant hepatic impairment (Child-Pugh Class B or C). The liver's inability to metabolize the hormones can lead to dangerously high systemic levels and further liver damage. If liver function tests become abnormal during use, the patch must be removed immediately.

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or are currently nursing.

Norelgestromin is a progestational agonist. Its primary molecular target is the progesterone receptor (PR). When norelgestromin binds to the PR in the hypothalamus, it inhibits the frequency of pulses of gonadotropin-releasing hormone (GnRH). This suppression prevents the pituitary gland from releasing the LH surge required for ovulation. Furthermore, norelgestromin has low androgenic activity, meaning it has a lower affinity for androgen receptors compared to older progestins like levonorgestrel, which may result in fewer side effects like acne or hirsutism.

The pharmacodynamics of norelgestromin are characterized by the suppression of the HPO axis. In addition to preventing ovulation, it causes the cervical mucus to become thick and cellular, which decreases sperm migration. It also produces an endometrium that is out of phase with the normal cycle, preventing the successful implantation of a zygote. The duration of effect lasts as long as the patch is applied, with a rapid return to baseline hormonal function within 24-48 hours of patch removal.

| Parameter | Value |

|---|---|

| Bioavailability | High (Transdermal bypasses first-pass) |

| Protein Binding | 99% (Primarily to Albumin) |

| Half-life | ~28 hours (after patch removal) |

| Tmax | 48 hours (to reach steady state) |

| Metabolism | Hepatic (Hydroxylation and conjugation) |

| Excretion | Renal 50%, Fecal 50% |

• Molecular Formula: C21H29NO2
• Molecular Weight: 327.46 g/mol
• Solubility: Lipophilic (soluble in fats/oils), which facilitates its passage through the skin's lipid barrier.
• Structure: It is the 17-deacetylated metabolite of norgestimate. It contains a 19-norsteroid backbone with an oxime group at the C3 position, which is critical for its progestogenic activity.

Norelgestromin is classified as a Progestin [EPC] and is used as part of a Combined Hormonal Contraceptive. Related medications include norgestimate (its parent compound), desogestrel, and gestodene, which are also considered third-generation progestins known for their high potency and lower androgenic profiles.